del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis. 1 nov 2002;186(9):1366‑70. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/12402211
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (London, England). 13 juill 2002;360(9327):119‑29. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/12126821
Tassie J-M, Grabar S, Lancar R, Deloumeaux J, Bentata M, Costagliola D, et al. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. J Acquir Immune Defic Syndr. 1 mai 2002;30(1):81‑7. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/12048367
